Article ; Online: Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
Drug design, development and therapy
2019 Volume 13, Page(s) 1515–1525
Abstract: Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver ... ...
Abstract | Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver transplantation and small molecule stabilizers were not effective in stopping disease progression. Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study. |
---|---|
MeSH term(s) | Amyloid Neuropathies, Familial/drug therapy ; Animals ; Humans ; Oligodeoxyribonucleotides, Antisense/therapeutic use ; Oligonucleotides/therapeutic use |
Chemical Substances | Oligodeoxyribonucleotides, Antisense ; Oligonucleotides ; Inotersen (0IEO0F56LV) |
Language | English |
Publishing date | 2019-05-06 |
Publishing country | New Zealand |
Document type | Journal Article ; Review |
ZDB-ID | 2451346-5 |
ISSN | 1177-8881 ; 1177-8881 |
ISSN (online) | 1177-8881 |
ISSN | 1177-8881 |
DOI | 10.2147/DDDT.S162913 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.